SYNARC will be Exhibiting and Presenting at the Alzheimer’s Association 2011 (AAICAD)
San Francisco – June 30, 2011 - SYNARC, the world’s leading provider of medical imaging services and novel biomarkers for the pharmaceutical, biotechnology, and medical device industries, announced today that the company will be exhibiting and presenting at the Alzheimer’s Association 2011 International Conference on Alzheimer’s Disease (AAICAD) being held July 16-21, 2011 in Paris.
SYNARC will have members of its scientific, business development, and technical teams on-hand at booth #117 to address how SYNARC is applying novel imaging techniques and new analysis algorithms to its industry-leading capabilities in AD trials. Of particular note, SYNARC’s scientific poster
presentations address its latest findings in the detection of vasogenic edema and microhemorrhages in AD patient populations, an area of increasing interest and concern to the field.
In addition, an oral presentation on a novel serum biomarker of Tau degradation for the detection of Alzheimer’s disease, the first such biomarker in the world, will be given by Morten Karsdal, PhD., Director of R&D for Nordic Bioscience, with whom Synarc has an exclusive agreement for access to technology.The presentation details are listed below:
Presentation Date: Monday, July 18, 2011
Presentation Number: O2-01-01
Presentation Time: 4:15pm -4:30pm
Title: A novel serum biomarker measuring degradation of Tau allows the detection of Alzheimer's disease in serum samples
Session Name: Novel Biomarkers in CSF and Blood
Poster Date: Wednesday, July 20, 2011
Poster Time: 12:30-3 p.m.
1st Poster Title: Vasogenic Edema in the setting of ß-amyloid lowering therapy, adverse event: what is it and how is it detected?
2nd Poster Title: Prevalence of Vasogenic Edema and Microhemorrhage in an Alzheimer's Disease Study Population at Baseline
Synarc’s medical image analysis, biochemical marker, and clinical research center services enable life-science industry clients to execute clinical trials accurately while decreasing the time, uncertainty, and cost of product development. Synarc has partnered with industry leaders to bring numerous leading compounds to market across a broad spectrum of therapeutic areas. Our services integrate critical aspects of clinical trial design and execution, from protocol design and subject recruitment to regulatory liaison on behalf of our clients. Our expert radiologists and scientists are innovators in all aspects of medical image analysis and biochemical markers in drug development, and have pioneered many methods used in today’s clinical trials.
# # #